Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma
Actas Dermosifiliogr (Engl Ed). 2021 Apr;112(4):295-301.
doi: 10.1016/j.ad.2020.11.002.
Epub 2020 Nov 13.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, España.
- 2 Servicio de Dermatología, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, España.
- 3 Servicio de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, España.
- 4 Servicio de Dermatología, Hospital Universitario La Fe. Grupo de Investigación «Dermatología y Regeneración Tisular», Instituto de Investigación Sanitaria La Fe, Universidad de Valencia, Valencia, España.
- 5 Unidad de Gestión Clínica de Dermatología, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, España.
- 6 Servicio de Dermatología, Hospital Clínic Barcelona, Grupo de investigación «Melanoma: Imaging, genetics and immunolog» del Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Barcelona, España; Centro de Investigación biomédica en Red de Enfermedades raras. (CIBERER), Instituto de Salud Carlos III, Barcelona, España. Electronic address: spuig@clinic.cat.
Abstract
Sonidegib is an antagonist of the transmembrane protein Smoothened in the Hedgehog signaling pathway. It is indicated for the treatment of locally advanced basal cell carcinoma (BCC) that is not amenable to curative surgery or radiotherapy. Sonidegib's efficacy and safety were demonstrated in the phase 2 BOLT trial, where 61% (95% CI, 48-72%) of patients with locally advanced BCC treated with sonidegib 200 mg achieved an objective response to treatment with a mean time to response of 4 months. The median duration of response was 26.1 months and the median progression-free survival was 22.1 months. The most common adverse events were muscle spasms (54.4%), hair loss (49.4%), and loss of taste (44.3%); most events were grade 1 or 2. In this review, we summarize the main findings on the efficacy, safety, and tolerability of sonidegib and discuss the management of locally advanced BCC with this drug.
Keywords:
Carcinoma basocelular localmente avanzado; Hedgehog pathway inhibitors; Hedgehog signaling pathway; Inhibidores de la vía Hedgehog; Locally advanced basal cell carcinoma; Sonidegib; Vía de señalización Hedgehog.
Copyright © 2020 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Antineoplastic Agents* / adverse effects
-
Biphenyl Compounds
-
Carcinoma, Basal Cell* / drug therapy
-
Hedgehog Proteins / therapeutic use
-
Humans
-
Pyridines
-
Skin Neoplasms* / drug therapy
Substances
-
Antineoplastic Agents
-
Biphenyl Compounds
-
Hedgehog Proteins
-
Pyridines
-
sonidegib